Zai Lab Starts China Phase III Trial Of Lead Drug In Ovarian Cancer
September 29, 2017 -- Shanghai's Zai Lab has dosed the first patient in a China Phase III trial of its lead drug, a PARP inhibitor. ZL-2306 (niraparib) will be tested as a second-line maintenance therapy in patients with platinum-responsive recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer. Tesaro, from whom Zai in-licensed greater China rights to the drug in 2016, was approved to market niraparib in the US earlier this year for these indications. Last week, Zai staged a very successful US IPO, raising $172.5 million.